Blueprint Medicines Corp
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.70 billion
- Book Value:
- Revenue TTM:
- $204.04 million
- Operating Margin TTM:
- Gross Profit TTM:
- $177.28 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Blueprint Medicines Corp had its IPO on 2015-04-30 under the ticker symbol BPMC.
The company operates in the Healthcare sector and Biotechnology industry. Blueprint Medicines Corp has a staff strength of 641 employees.
Shares of Blueprint Medicines Corp opened at $44.76 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $44 - $45.63, and closed at $45.09.
This is a +0.22% increase from the previous day's closing price.
A total volume of 999,200 shares were traded at the close of the day’s session.
In the last one week, shares of Blueprint Medicines Corp have increased by +4.47%.
Blueprint Medicines Corp's Key Ratios
Blueprint Medicines Corp has a market cap of $2.70 billion, indicating a price to book ratio of 4.3665 and a price to sales ratio of 9.6137.
In the last 12-months Blueprint Medicines Corp’s revenue was $204.04 million with a gross profit of $177.28 million and an EBITDA of $-525783008. The EBITDA ratio measures Blueprint Medicines Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Blueprint Medicines Corp’s operating margin was -263.44% while its return on assets stood at -25.82% with a return of equity of -75.07%.
In Q4, Blueprint Medicines Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 63.8%.
Blueprint Medicines Corp’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-9.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Blueprint Medicines Corp’s profitability.
Blueprint Medicines Corp stock is trading at a EV to sales ratio of 6.9888 and a EV to EBITDA ratio of -2.7283. Its price to sales ratio in the trailing 12-months stood at 9.6137.
Blueprint Medicines Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.35 billion
- Total Liabilities
- $183.23 million
- Operating Cash Flow
- Capital Expenditure
- $1.48 million
- Dividend Payout Ratio
Blueprint Medicines Corp ended 2023 with $1.35 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.35 billion while shareholder equity stood at $514.68 million.
Blueprint Medicines Corp ended 2023 with $0 in deferred long-term liabilities, $183.23 million in other current liabilities, 60000.00 in common stock, $-1832958000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $119.71 million and cash and short-term investments were $944.99 million. The company’s total short-term debt was $27,430,000 while long-term debt stood at $535.28 million.
Blueprint Medicines Corp’s total current assets stands at $1.05 billion while long-term investments were $133.48 million and short-term investments were $825.28 million. Its net receivables were $23.53 million compared to accounts payable of $2.73 million and inventory worth $29.70 million.
In 2023, Blueprint Medicines Corp's operating cash flow was $-53283000.00 while its capital expenditure stood at $1.48 million.
Comparatively, Blueprint Medicines Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Blueprint Medicines Corp stock is currently trading at $45.09 per share. It touched a 52-week high of $79.4 and a 52-week low of $79.4. Analysts tracking the stock have a 12-month average target price of $69.41.
Its 50-day moving average was $45.22 and 200-day moving average was $53.08 The short ratio stood at 8.73 indicating a short percent outstanding of 0%.
Around 77.3% of the company’s stock are held by insiders while 10710.9% are held by institutions.
Frequently Asked Questions About Blueprint Medicines Corp
Similar Industry Stocks (Biotechnology)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.